Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,174 across all filing types
Latest filing 2024-09-05 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Loss of Share Certificates
Regulatory Filings Classification · 100% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, related to the loss of share certificates. It contains details of shareholders and lost share certificates. The document is short (2723 characters) and is a regulatory compliance communication rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or any report type content. It is also not an announcement of voting results, board changes, or capital changes. The document fits best under Regulatory Filings (RNS) as it is a regulatory compliance certificate related to share certificate loss reporting.
2024-09-05 English
Intimation regarding loss of share certificate by the shareholders.
Regulatory Filings Classification · 100% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, related to the loss of share certificates. It is addressed to stock exchanges and signed by the company secretary. The content is a regulatory compliance update about shareholder share certificate loss, not a financial report, earnings release, or management discussion. It is a formal regulatory filing to comply with stock exchange rules. The document length is short (2723 characters) and contains no financial data or report. Therefore, it fits best under Regulatory Filings (RNS).
2024-09-05 English
Lupin Launches Mirabegron Extended-Release Tablets in the United States.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Mirabegron Extended-Release Tablets) in the United States following FDA approval. It is addressed to stock exchanges and references regulatory disclosure requirements (SEBI Listing Regulations). The content is promotional and informational about a product launch, not a financial report, earnings release, or regulatory filing about financials or governance. It does not contain financial statements, management discussion, voting results, or legal proceedings. It is a typical corporate announcement of a business development. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-04 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Mirabegron Extended-Release Tablets) in the United States following FDA approval. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The content is promotional and informational about a product launch, not a financial report, earnings release, or regulatory filing about financial performance or corporate governance. It does not contain financial statements, management discussion, or voting results. It is a typical corporate announcement about a business development. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-04 English
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Regulatory Filings Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about receipt of penalty orders from GST authorities and provides details of these orders in annexures. The document is an official regulatory announcement about a legal/regulatory matter affecting the company, Lupin Limited. It does not contain financial statements, earnings data, or detailed management discussion. It is not a full audit report or annual/interim report. It is not a voting result or AGM material. The document is primarily a regulatory compliance disclosure about legal penalties. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-02 English
Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about orders received from GST authorities imposing penalties on the company. The document includes details of the orders, dates, authorities involved, and the company's response. There are no financial statements or detailed financial analysis, nor is this a report or presentation. It is a regulatory announcement about a legal/penalty matter. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories like Legal Proceedings Report (LTR) because it is a compliance disclosure about penalties rather than a lawsuit or regulatory action update. The document length is about 5916 characters, and it is not a report publication announcement or certification. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2024-09-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.